Literature DB >> 27270163

Platelet-Monocyte Aggregates and C-Reactive Protein are Associated with VTE in Older Surgical Patients.

Lauren Shih1, David Kaplan1, Larry W Kraiss2, T Charles Casper3, Robert C Pendleton1, Christopher L Peters4, Mark A Supiano5, Guy A Zimmerman1, Andrew S Weyrich1,6, Matthew T Rondina1,6,7.   

Abstract

Emerging evidence implicates platelets as key mediators of venous thromboembolism (VTE). Nevertheless, the pathways by which platelets and circulating procoagulant proteins synergistically orchestrate VTE remain incompletely understood. We prospectively determined whether activated platelets and systemic procoagulant factors were associated with VTE in 32 older orthopedic surgery patients. Circulating platelet-monocyte aggregates (PMAs), p-selectin expression (P-SEL), and integrin αIIbβ3 activation (PAC-1 binding) were assessed pre-operatively and 24 hours post-operatively. The proinflammatory and procoagulant molecule C-reactive protein (CRP), which induces PMA formation in vitro, along with plasma d-dimer and fibrinogen levels were also measured. The primary outcome was VTE occurring within 30 days post-operatively. Overall, 40.6% of patients developed VTE. Patients with VTE had a significant increase in circulating PMAs and CRP post-operatively, compared to those without VTE. Changes in PMA and CRP in VTE patients were significantly correlated (r(2) = 0.536, p = 0.004). In contrast, P-SEL expression and PAC-1 binding, fibrinogen levels, and d-dimers were not associated with VTE. This is the first study to identify that increased circulating PMAs and CRP levels are early markers associated with post-surgical VTE. Our findings also provide new clinical evidence supporting the interplay between PMAs and CRP in patients with VTE.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27270163      PMCID: PMC4895334          DOI: 10.1038/srep27478

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Major orthopedic surgery, including total hip and knee arthroplasty (THA/TKA) increases the risk of venous thromboembolism (VTE). Older age is also a VTE risk factor, with an approximately 7–10 fold increased risk in adults less than 55 years old as compared to adults 75 years and older123. While comorbid conditions contribute to the increased incidence of VTE in older adults, aging-specific factors including platelet reactivity, endothelial dysfunction, and altered hemostatic responses are also thought to influence thrombosis risk but remain incompletely understood14. Emerging and established evidence implicates platelets as key cellular mediators of inflammation, vascular disease, and VTE56. As platelets are central to thrombin generation and fibrin deposition, and endothelial injury is common in surgical patients, increased platelet activation and interactions with target cells may contribute to post-surgical VTE57. Moreover, indices of platelet activation may serve to identify patients at increased risk of VTE and thus guide more effective measures to prevent thrombosis. One of the most sensitive markers of in vivo platelet activation is increased circulating platelet-monocyte aggregates (PMAs). PMAs are associated with adverse clinical outcomes in older septic patients89 and in patients with arterial thrombosis81011, but have not been studied in older adults undergoing orthopedic surgery. The pro-inflammatory and pro-coagulant molecule C-reactive protein1213 (CRP) is tied to an increased risk of cardiovascular disease. Interestingly, in experimental models, CRP promotes PMA formation and platelet adhesion to endothelial cells141516. Nevertheless, studies investigating whether circulating PMAs and CRP may mediate VTE in human thrombotic disease settings remain absent. The goal of this study was to determine whether increased circulating PMA formation and CRP levels are associated with post-operative VTE in older adults undergoing orthopedic surgery.

Results

Clinical Features and Thrombotic Events in the Study Cohort

We prospectively studied 32 patients, who had an average age of 65.5 ± 7.1 years (Table 1). There was no clinical evidence of VTE pre-operatively in these patients. Almost all patients (n = 31/32, 96.9%) underwent surgery for degenerative joint disease due to osteoarthritis. VTE was diagnosed in 40.6% (n = 13/32) of patients and most thrombotic events were DVT (Table 2). All VTE events were diagnosed on the initial compression ultrasound (CUS). The second ultrasound done 14 days post-operatively showed in some cases partial thrombus resolution but did not identify any new DVT. One patient presented with symptomatic PE diagnosed by CT pulmonary angiography. Distal DVT was more common than proximal DVT (76.9% vs. 23.1%, p = 0.09). Of patients with distal DVT (n = 10), three had bilateral distal DVT. Of patients with unilateral distal DVT, four were ipsilateral and one was contralateral to the surgical site, and two occurred in the setting of bilateral TKA. There were no differences in age, gender, BMI, surgery type, tourniquet time (for TKA), or baseline laboratory values between patients with and without VTE (Table 1). Post-operative bleeding and infectious complications were uncommon (Table 2). The identification of DVT altered clinical management with extended duration warfarin monotherapy and/or the use of enoxaparin in addition to warfarin in most patients (Table 2). As expected, patients diagnosed with VTE had a higher TTR and a longer duration of anticoagulation than patients without VTE (62.1% vs. 40%, p < 0.05 and 61.0 ± 11 days vs. 17.4 ± 5.0 days, respectively; p < 0.001), highlighting that a diagnosis of VTE altered clinical management.
Table 1

Characteristics of the study cohort and comparisons between patients with and without venous thromboembolism (VTE).

 Overall (n = 32)No VTE (n = 19)VTE (n = 13)Pvalue
Demographics & Clinical Features
 Age, years65.6 ± 7.165.6 ± 8.065.5 ± 5.70.95
 Male Gender, n (%)14 (43.8%)7 (36.8%)7 (53.8%)0.91
 BMI, kg/m230.8 ± 6.530.4 ± 6.531.4 ± 6.70.67
 Obesity (BMI ≥ 30kg/m2), n (%)17 (53.1%)8 (47.4%)8 (61.5%)0.43
Baseline Pre-operative Values
 Hemoglobin, mg/dL13.6 ± 1.213.5 ± 1.313.9 ± 1.10.29
 Platelets, K/uL282 ± 62274 ± 52292 ± 750.44
 White Blood Cell Count, K/uL7.4 ± 2.67.4 ± 3.17.3 ± 1.80.99
 International Normalized Ratio1.0 ± 0.11.0 ± 0.11.0 ± 0.10.91
 Prothrombin Time, sec13.1 ± 0.613.1 ± 0.713.1 ± 0.70.92
 aPTT, sec31.4 ± 3.731.0 ± 2.432.0 ± 5.10.45
Surgical Characteristics
 Total knee arthroplasty (TKA), n (%)23 (71.9%)13 (68.4%)10 (76.9%)0.70
 Unilateral TKA, n (%)20 (62.5%)13 (68.4%)7 (53.8%)0.07
 Bilateral TKA, n (%)3 (9.4%)0 (0%)3 (100%)0.07
 Total hip arthroplasty (THA), n (%)9 (29.1%)6 (31.6%)3 (23.1%)0.70
 Tourniquet time (for TKA), min.56.1 ± 12.655.5 ± 16.056.9 ± 7.00.80

Central tendency data are reported as mean (±SD) unless otherwise specified (BMI: body mass index; aPTT: activated partial thromboplastin time).

Table 2

Anticoagulation management and clinical outcomes of the study cohort.

Anticoagulation ManagementValue
 Duration of OAC, days (median [IQR])19 (13–29)
 Overall cTTR, (%)51%
 Days to INR > 1.9 (median [IQR])5 (4–8)
 Post Operative Aspirin Use, n (%)4 (12.9%)
Thrombotic Outcomes¥
 Any VTE, n (%)13 (41.9%)
 Proximal DVT, n (%)3 (9.6%)
 Unilateral Distal DVT, n (%)7 (22.6%)
 Bilateral Distal DVT, n (%)3 (9.6%)
 Pulmonary Embolism, n (%)1 (3.2%)
Bleeding and Infection Outcomes
 Major Bleeding, n (%)0 (0%)
 Clinically-Relevant Non-Major Bleeding, n (%)1 (3.2%)
 Infection, n (%)2 (6.4%)
VTE Treatment
 Extended Duration of Warfarin Monotherapy, n (%)3 (23.1%)
 Enoxaparin plus Warfarin, n (%)8 (61.5%)
 Standard Duration of Warfarin Monotherapy, n (%)2 (15.4%)

Central tendency data are reported as mean ± SD unless otherwise specified (cTTR: center-specific time in therapeutic range; INR: international normalized ratio; OAC: oral anticoagulation; ¥patients may have had DVT with or without pulmonary embolism and thus the total number of events may exceed 13).

Circulating PMAs and CRP were Associated with VTE

Circulating PMAs were significantly increased in patients with VTE on POD1 whereas those without VTE had unchanged (or slightly reduced) circulating PMAs (Fig. 1A). P-SEL expression was unchanged post-operatively and did not differ significantly between patients with and without VTE (Fig. 1B). Platelet integrin αIIbβ3 activation increased post-operatively but did not significantly differ between patients with and without VTE (Fig. 1C). In pre-specified subgroup analyses excluding patients given aspirin post-operatively (n = 13), post-operative changes in circulating PMA levels remained significantly higher in patients with VTE compared to those without VTE (fold-change of 1.48 ± 0.20 vs. 0.65 ± 0.14, p < 0.01).
Figure 1

Increased circulating platelet-monocyte aggregates (PMAs) are associated with post-operative VTE.

Circulating PMAs, platelet surface P-selectin expression (P-SEL), and integrin αIIbβ3 activation were measured by whole blood flow cytometry immediately prior to surgery and again 24 hours post-operatively. The number of PMAs, the expression of P-SEL, and integrin αIIbβ3 activation post-operatively was compared to pre-operative (or baseline) values and the fold-change was determined for each patient. (A) Circulating numbers of PMAs were significantly increased post-operatively in patients who developed VTE (+VTE, n = 13), compared to patients without VTE (−VTE, n = 19). In comparison, neither (B) P-SEL expression nor (C) integrin αIIbβ3 activation was associated with VTE. Data show the mean ± SEM for each group.

CRP levels were also significantly increased in patients with VTE (Fig. 2A). Increases in CRP, which has been demonstrated to orchestrate PMA formation in vitro14, correlated significantly and positively with increased PMAs (Fig. 2B). CRP levels were not correlated with P-SEL expression (r2 = 0.04, p = 0.25) or integrin αIIbβ3 activation (r2 = 0.005, p = 0.69). Plasma levels of d-dimer rose following surgery, as expected, but were not associated with VTE (Fig. 2C) and did not significantly correlate with PMAs (r2 = 0.37, p = 0.08). Plasma fibrinogen levels remained generally unchanged after surgery and did not differ between patients who developed VTE and those who did not (Fig. 2D).
Figure 2

C-reactive protein (CRP) is increased in patients with VTE and correlates with platelet-monocyte aggregates (PMAs).

Plasma was harvested from whole blood collected immediately pre-operatively and again 24 hours post-operatively in all patients. Levels of CRP, d-dimer, and fibrinogen were measured. Shown is the fold-change post-operatively compared to pre-operative (e.g. baseline) levels in each patient. (A) Changes in CRP were significantly higher in patients who developed VTE (+VTE, n = 13), compared to patients without VTE (−VTE, n = 19) and (B) correlated with increased PMAs. In contrast, changes in (C) d-dimer and (D) fibrinogen did not significant differ between patients who developed VTE and those who did not develop VTE. Data show the mean ± SEM for each group. The Pearson’s coefficient (r2) was determined for the correlation between CRP and PMAs.

Discussion

Here we prospectively show for the first time that increased circulating PMAs following orthopedic surgery are associated with VTE in older patients. Moreover, increased CRP was also associated with VTE and significantly correlated with changes in circulating PMAs. Increased levels of both circulating PMAs and plasma CRP have been tied to cardiovascular disease in humans. While still incompletely understood, emerging evidence suggests that CRP may have previously unrecognized pro-thrombotic effects. CRP increases the expression of adhesion molecules and plasminogen-activator inhibitor 1 (PAI-1) in endothelial cells1217 and the expression of tissue factor (TF) in monocytes18. Transgenic mice infused with human CRP exhibit increased thrombosis and in human volunteers infused with exogenous CRP, there is an increase in pro-thrombotic factors1319. CRP induces platelet adhesion to endothelial cells1516, one of the initial critical steps for vascular thrombosis. Importantly, CRP also promotes PMA formation in vitro and in vivo models of transgenic mice. In the REGARDS study, which examined inflammatory markers and incident VTE in 30,239 subjects, higher CRP levels were associated with an increased risk of VTE20. Our findings that increases in CRP correlated with PMAs and were associated with VTE in orthopedic surgery, a setting where inflammation and vascular wall damage occur, provides further evidence supporting the link between platelet activation, CRP, and thrombosis. The results of this investigation extend published studies demonstrating that circulating PMAs are sensitive markers of in vivo platelet activation and are consistent with findings in older patients with other acute thrombotic and inflammatory conditions8910. Platelet surface P-selectin expression, which mediates adhesion of platelets to monocytes, was not associated with VTE in our study. This is similar to other studies of P-selectin and thrombosis in orthopedic surgery21, perhaps due in part to the rapid shedding of P-selectin from the platelet surface once activated. In addition, once stimulated, platelets may adhere to injured or activated endothelial cells and to growing thrombus. The results of our study are also consistent with previous studies of plasma-based platelet activation markers in surgery. For example, levels of ADAMTS13, von Willebrand factor, platelet factor 4, and CD40 ligand, which are all secreted by platelets when activation, increase post-operatively and, in some settings, correlate with thrombosis risk2223. Finally, as PMA formation mediates pro-inflammatory gene synthesis and associated pro-thrombotic responses5, these findings support the role of platelets as mediators in the pathogenesis of VTE. PMA formation in infectious and inflammatory settings is dysregulated in older adults, leading to exaggerated cytokine synthesis and adverse clinical outcomes9. Our results build upon these clinical studies in older populations, demonstrating that PMAs are also associated with thrombotic events following orthopedic surgery. As both older age and orthopedic surgery are risk factors for VTE, and measurements of PMAs and CRP in this study were made immediately before and 24 hours after surgery, our findings, may lead to improvements in VTE risk stratification and early diagnosis in this higher risk population, if confirmed in larger studies. The strengths of this study include the prospective design, our rigorous assessment of in vivo platelet activation by three distinct indices, our inclusion of correlative plasma procoagulant markers for comparison, and our comprehensive assessment of VTE, including the use of bilateral, comprehensive duplex venous ultrasonography at two time points postoperatively. While the majority of VTE that occurred in our patients was distal DVT, consistent with published reports in this population24, these thrombotic events were clinically significant, resulting in extension of anti-thrombotic therapy. Moreover, approximately one-third of these distal DVTs were bilateral, which are associated with higher rates of recurrence and mortality than unilateral distal DVT252627. Thus, while the management of distal DVT remains controversial, in our older surgical patients in our study, identification of thrombotic events influenced patients’ treatments. While d-dimer levels increased post-operatively, they were not associated with VTE. Increases in D-dimer are a sensitive, albeit non-specific, diagnostic tool in patients with suspected VTE and helps guide clinical evaluations. Our data suggest that d-dimer may have less utility in the early post-operative period for identifying patients at increased risk of post-surgical VTE. We also identified a relatively high frequency of DVT. Reasons for this are not entirely clear and may be due to the timing of the US relative to surgery or changing demographics in this population and the older age of the cohort. As all patients received guideline-recommended thromboprophylaxis28, however, we do not believe that this high incidence reflects suboptimal VTE prophylaxis management. While not a primary focus of this study, our findings also suggest that in selected high-risk patients (perhaps those with evidence of enhanced in vivo platelet activation), more aggressive early anticoagulation may be needed. Finally, while prospective in nature and rigorous in design, our study is limited by the small sample size and further studies are needed to further examine platelet activation and VTE in older adults.

Conclusions

In conclusion, this study identifies that increased circulating numbers of PMAs and CRP levels within 24 hours after major orthopedic surgery are early markers associated with VTE in older adults.

Methods

Patient Recruitment

The University of Utah Institutional Review Board (IRB # 26265) approved this study, all patients provided informed consent, and all methods were carried out in accordance with IRB approved guidelines. Adults undergoing elective THA or TKA (American Society of Anesthesiologists Physical Class I or II) were included. Patients with a history of venous or arterial thrombosis, known thrombophilia, uncontrolled hypertension (BP ≥ 160/95 mmHg), chronic kidney or liver disease, or surgery, hospitalization, acute coronary syndrome, or red blood cell or platelet transfusions within 30 days prior to surgery were excluded. No patients received pre-operative anticoagulation. NSAIDS were discontinued ≥7 days pre-operatively in all patients. Patients taking aspirin (81–162 mg daily) pre-operatively were allowed to continue the aspiring if recommended by their physician; otherwise aspirin was stopped ≥7 days prior to surgery. Demographic and clinical data were prospectively captured for all patients. Routine laboratory data and the procoagulant factors CRP, d-dimer, and fibrinogen concentration were measured immediately prior to surgery and 24 hours post-operatively (e.g. post-operative day 1; POD1) by a national reference laboratory using standard quality controls. The primary outcome was the development of any VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE) within 30 days post-operatively. Patients were also followed for any major or clinically relevant non-major (CRNM) bleeding29. Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical organ, extra surgical site bleeding causing a fall in hemoglobin level of ≥2.0 g/L leading to transfusion, surgical site bleeding requiring a second intervention, or unexpected and prolonged surgical site bleeding resulting in hemodynamic instability and transfusion. CRNM bleeding was defined as overt bleeding not meeting the criteria for a major bleeding event but associated with medical intervention, unscheduled contact with a physician, or discomfort or impairment of activities of daily life.

Platelet Activation Studies

Whole blood was carefully drawn via peripheral venipuncture into sterile acid-citrate-dextrose BD vacutainer tubes®. The first 5mLs of blood were discarded and the remaining blood was immediately transported at room temperature to the laboratory without agitation. Blood samples were drawn between the hours of 7–10AM immediately prior to surgery and at the same time on POD1, simultaneous when clinical laboratory parameters and procoagulant markers were measured. Platelet integrin αIIbβ3 binding, platelet surface p-selectin expression (P-SEL), and circulating numbers of PMAs, indices of in vivo platelet activation, were assessed in unstimulated whole blood by flow cytometry within 20 minutes of blood collection as previously described93031. Briefly, whole blood was incubated with the platelet marker CD41 phycoerythrin and the monocyte marker CD14 (for PMAs), the fluorescein isothiocyanate monoclonal antibody for PAC-1 (binds to the active conformation of integrin αIIbβ3), or CD62 (for P-SEL). Samples were analyzed with a FACScan Analyzer and CellQuest software. Antibodies were obtained from BD Biosciences. Integrin αIIbβ3 activation, P-SEL expression, and circulating PMAs were adjusted for non-specific binding. Changes in these indices of in vivo platelet activation (defined as the fold-change between pre-operative and POD1 values) were determined for each patient.

Thromboprophylaxis

Adjusted-dose warfarin monotherapy (target INR 2.0–2.5 per institutional guidelines) was used post-operatively for VTE prophylaxis. Warfarin was initiated the evening after surgery and managed by a team of anticoagulation specialists using a warfarin nomogram32. Warfarin management was evaluated by determining time in therapeutic range (TTR)33. When VTE was diagnosed, the patient’s medical team made all anticoagulant treatment decisions. The use of parenteral anticoagulants and duration of anticoagulation was prospectively recorded. Intermittent compression devices and compression stockings were used post-operatively in all patients.

Compression Ultrasonography

Registered vascular technologists performed comprehensive bilateral, lower extremity duplex compression ultrasonography (CUS) on all patients at two time points following surgery. The first CUS was performed prior to hospital discharge and a second CUS was performed approximately 14 days postoperatively, per standardized protocol34. Briefly, the following deep veins of the thigh and calf were examined in a sequential manner in 1–2 cm increments: common femoral vein, mid and distal femoral vein, popliteal vein, trifurcation of the deep calf veins, posterior tibial veins, the gastrocnemius veins, soleal sinus vein, and peroneal veins. Lack of venous compressibility with the ultrasound transducer held in a transverse position to the vein was interpreted as a positive study. Absent or diminished color flow and pulse wave doppler with failure of augmentation further confirmed the presence of DVT. A board-certified vascular surgeon, blinded as to the patient’s clinical information, measurements of in vivo platelet activation, and procoagulant markers, interpreted the CUS. Proximal DVT was defined as an acute-appearing thrombosis involving the popliteal and/or more proximal lower extremity deep vein segments. Distal DVT was defined as an acute appearing thrombosis in any deep vein segment distal to the popliteal vein.

Statistical Analyses

Data were examined for normality using skewness and kurtosis tests. Groups were compared using the student’s t-test or Wilcoxon Rank Sum and the Chi-squared or Fisher’s exact test, as appropriate (GraphPad Prism v6.0, La Jolla, CA). Central tendency data are reported as the mean or median (interquartile range, IQR) if the distribution was skewed. Pearson’s regression analyses were performed to analyze correlations. A p-value < 0.05 was considered statistically significant.

Additional Information

How to cite this article: Shih, L. et al. Platelet-Monocyte Aggregates and C-Reactive Protein are Associated with VTE in Older Surgical Patients. Sci. Rep. 6, 27478; doi: 10.1038/srep27478 (2016).
  34 in total

1.  In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1).

Authors:  Matthew T Rondina; BreAnna Brewster; Colin K Grissom; Guy A Zimmerman; Diana H Kastendieck; Estelle S Harris; Andrew S Weyrich
Journal:  Chest       Date:  2012-03-01       Impact factor: 9.410

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy.

Authors:  Haim D Danenberg; Neelesh Kantak; Etty Grad; Rajesh V Swaminathan; Chaim Lotan; Elazer R Edelman
Journal:  Eur J Haematol       Date:  2007-01-23       Impact factor: 2.997

4.  Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty.

Authors:  K Kageyama; Y Nakajima; M Shibasaki; S Hashimoto; T Mizobe
Journal:  J Thromb Haemost       Date:  2007-04       Impact factor: 5.824

5.  Site and clinical outcome of deep vein thrombosis of the lower limbs: an epidemiological study.

Authors:  C Seinturier; J L Bosson; M Colonna; B Imbert; P H Carpentier
Journal:  J Thromb Haemost       Date:  2005-05-09       Impact factor: 5.824

6.  Whole blood flow cytometry measurements of in vivo platelet activation in critically-Ill patients are influenced by variability in blood sampling techniques.

Authors:  Matthew T Rondina; Colin K Grissom; Shaohua Men; Estelle S Harris; Hansjorg Schwertz; Guy A Zimmerman; Andrew S Weyrich
Journal:  Thromb Res       Date:  2011-12-16       Impact factor: 3.944

7.  Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty.

Authors:  Ling Liu; Jing Ling; Zhenni Ma; Quan Yuan; Jun Pan; Huilin Yang
Journal:  Mol Med Rep       Date:  2014-12-03       Impact factor: 2.952

8.  Deep vein thrombosis in orthopedic surgery.

Authors:  Marcella Calfon; Ali Seddighzadeh; Gregory Piazza; Samuel Z Goldhaber
Journal:  Clin Appl Thromb Hemost       Date:  2009-06-01       Impact factor: 2.389

9.  C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

Authors:  Sridevi Devaraj; Dan Yan Xu; Ishwarlal Jialal
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

10.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

View more
  11 in total

1.  Altered functions of platelets during aging.

Authors:  Emilie Montenont; Matthew T Rondina; Robert A Campbell
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

2.  Granzyme A in Human Platelets Regulates the Synthesis of Proinflammatory Cytokines by Monocytes in Aging.

Authors:  Robert A Campbell; Zechariah Franks; Anish Bhatnagar; Jesse W Rowley; Bhanu K Manne; Mark A Supiano; Hansjorg Schwertz; Andrew S Weyrich; Matthew T Rondina
Journal:  J Immunol       Date:  2017-11-22       Impact factor: 5.422

3.  Longitudinal assessment of the platelet transcriptome in advanced heart failure patients following mechanical unloading.

Authors:  Callie Frey; Antigoni G Koliopoulou; Emilie Montenont; Neal D Tolley; Hadi Javan; Stephen H McKellar; Stavros G Drakos; Craig H Selzman; Matthew T Rondina
Journal:  Platelets       Date:  2020-01-14       Impact factor: 3.862

4.  Post-Injury Platelet Aggregation and Venous Thromboembolism.

Authors:  Zachary A Matthay; Zane J Hellmann; Brenda Nunez-Garcia; Alexander T Fields; Joseph Cuschieri; Matthew D Neal; Jeffrey S Berger; Elliot Luttrell-Williams; M Margaret Knudson; Mitchell J Cohen; Rachael A Callcut; Lucy Z Kornblith
Journal:  J Trauma Acute Care Surg       Date:  2022-04-21       Impact factor: 3.697

Review 5.  Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis.

Authors:  Milka Koupenova; Lauren Clancy; Heather A Corkrey; Jane E Freedman
Journal:  Circ Res       Date:  2018-01-19       Impact factor: 17.367

Review 6.  Modulators of platelet function in aging.

Authors:  Krishna S Iyer; Sanjana Dayal
Journal:  Platelets       Date:  2019-09-16       Impact factor: 3.862

7.  Nomogram predicted risk of peripherally inserted central catheter related thrombosis.

Authors:  Nan Hao; Xin Xie; Zhangjian Zhou; Jieqiong Li; Li Kang; Huili Wu; Pingli Guo; Chengxue Dang; Hao Zhang
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

Review 8.  The dual role of platelet-innate immune cell interactions in thrombo-inflammation.

Authors:  Julie Rayes; Joshua H Bourne; Alexander Brill; Steve P Watson
Journal:  Res Pract Thromb Haemost       Date:  2019-10-17

9.  Immunological analysis and differential genes screening of venous thromboembolism.

Authors:  Li-Na Gao; Qiang Li; Jian-Qin Xie; Wan-Xia Yang; Chong-Ge You
Journal:  Hereditas       Date:  2021-01-02       Impact factor: 3.271

Review 10.  Platelet-Leucocyte Aggregates as Novel Biomarkers in Cardiovascular Diseases.

Authors:  Kinga Pluta; Kinga Porębska; Tomasz Urbanowicz; Aleksandra Gąsecka; Anna Olasińska-Wiśniewska; Radosław Targoński; Aleksandra Krasińska; Krzysztof J Filipiak; Marek Jemielity; Zbigniew Krasiński
Journal:  Biology (Basel)       Date:  2022-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.